Valuation : MBody AI

Market Cap 19.76M 17.04M 16.03M 14.6M 27.46M 1.88B 27.61M 190M 73.76M 954M 74.18M 72.57M 3.16B P/E 2024
-0.23x
P/E 2025 2.44x
Enterprise Value 19.55M 16.87M 15.87M 14.45M 27.18M 1.86B 27.33M 188M 73.01M 944M 73.41M 71.82M 3.13B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day-0.76%
1 week-3.24%
Current month-3.24%
1 month-17.07%
3 months-43.88%
6 months-46.75%
Current year-42.15%
1 month 6.22
Extreme 6.22
10.48
Current year 6.22
Extreme 6.22
27.44
1 year 4.41
Extreme 4.410001
27.44
3 years 3.92
Extreme 3.920001
32.38
5 years 3.92
Extreme 3.920001
183.4
10 years 3.92
Extreme 3.920001
4,956

Financials

2024 2025
Net sales - -
Net income -25.15M -21.69M -20.41M -18.59M -34.96M -2.39B -35.15M -241M -93.9M -1.21B -94.42M -92.37M -4.03B 4.14M 3.57M 3.36M 3.06M 5.75M 393M 5.79M 39.71M 15.46M 200M 15.54M 15.21M 663M
Net Debt -129K -111K -105K -95.36K -179K -12.24M -180K -1.24M -482K -6.23M -484K -474K -20.65M -203K -175K -165K -150K -282K -19.27M -284K -1.95M -758K -9.8M -762K -746K -32.5M
Logo MBody AI
Check-Cap Ltd. is an Israel-based clinical-stage medical diagnostics company focused on colorectal cancer (CRC) screening solutions. The Company develops C-Scan, a preparation-free and non-invasive screening system designed to detect precancerous polyps and structural abnormalities in the colon. Its technology uses an ingestible capsule with ultra-low-dose X-ray imaging to scan the colon and collect diagnostic data. The C-Scan platform consists of an ingestible capsule, body-worn tracking and data collection components, and proprietary software that processes information and generates visual maps of the colon. The Company develops diagnostic technologies for gastrointestinal screening and early disease detection.
Employees
85
Sector
-
Date Price Change Volume
26/08/26 US$6.780 -16.09% 45,484
25/08/26 US$8.080 +0.50% 19,625
  1. Stock Market
  2. Stocks
  3. MBAI Stock